Početna stranicaIMGN • BMV
add
ImmunoGen Ord Shs
Preth. zaklj. cijena
268,50 $
Godišnji raspon
268,50 $ - 268,50 $
Tržišna kapitalizacija
8,72 mlr. USD
P/E omjer
-
Prinos dividende
-
Vijesti s tržišta
Financijski podaci
Račun dobiti i gubitka
Prihod
Neto dohodak
| (USD) | ruj 2023.info | Godišnja promjena |
|---|---|---|
Prihod | 113,42 mil. | 637,72 % |
Operativni troškovi | 37,74 mil. | 12,26 % |
Neto dohodak | 30,75 mil. | 139,54 % |
Neto profitabilnost | 27,11 | 105,36 % |
Zarada po dionici | 0,10 | 132,26 % |
EBITDA | 26,38 mil. | 134,26 % |
Efektivna porezna stopa | −3,94 % | — |
Bilanca stanja
Ukupna imovina
Ukupne obveze
| (USD) | ruj 2023.info | Godišnja promjena |
|---|---|---|
Gotovinska i kratkoročna ulaganja | 605,54 mil. | 95,64 % |
Ukupna imovina | 822,10 mil. | 129,13 % |
Ukupne obveze | 260,50 mil. | 44,09 % |
Ukupni kapital | 561,60 mil. | — |
Dionice u optjecaju | 266,26 mil. | — |
Cijena prema knjigovodstvenoj vrijednosti | 127,25 | — |
Povrat imovine | 8,45 % | — |
Povrat kapitala | 10,17 % | — |
Tok novca
Neto promjena novca
| (USD) | ruj 2023.info | Godišnja promjena |
|---|---|---|
Neto dohodak | 30,75 mil. | 139,54 % |
Gotovina od poslovanja | 2,77 mil. | 104,31 % |
Gotovina iz ulaganja | −1,35 mil. | −124,92 % |
Gotovina iz financiranja | 32,13 mil. | 7.056,35 % |
Neto promjena novca | 33,55 mil. | 152,12 % |
Slobodan tok novca | −2,32 mil. | 91,72 % |
Više
ImmunoGen, Inc. was a biotechnology company focused on the development of antibody-drug conjugate therapeutics for the treatment of cancer. ImmunoGen was founded in 1981 and was headquartered in Waltham, Massachusetts.
An ImmunoGen ADC contains a manufactured antibody that binds to a target found on cancer cells, with one of the company's potent cell-killing agents attached as a "payload". The antibody serves to deliver the cell-killing agent specifically to cancer cells bearing its target and the payload serves to kill these cells. In some cases, the antibody also has anticancer activity.
In November 2023, AbbVie, an American pharmaceutical company, announced it was buying ImmunoGen for $10.1 billion. Wikipedia
Glavni izvršni direktor
Osnovano
1981
Web-lokacija
Zaposlenici
277
